Impel NeuroPharma, Inc. (IMPL)

NASDAQ: IMPL · IEX Real-Time Price · USD
8.72
+0.36 (4.31%)
At close: Aug 11, 2022 4:00 PM
8.90
+0.18 (2.06%)
After-hours: Aug 11, 2022 6:29 PM EDT
4.31%
Market Cap 202.09M
Revenue (ttm) 668,000
Net Income (ttm) -92.22M
Shares Out 23.18M
EPS (ttm) -4.57
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 37,538
Open 8.54
Previous Close 8.36
Day's Range 8.30 - 8.80
52-Week Range 5.72 - 34.75
Beta n/a
Analysts Buy
Price Target 41.14 (+371.8%)
Earnings Date Aug 15, 2022

About IMPL

Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidop... [Read more...]

Industry Biotechnology
IPO Date Apr 23, 2021
CEO Michael Hite
Employees 129
Stock Exchange NASDAQ
Ticker Symbol IMPL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for IMPL stock is "Buy." The 12-month stock price forecast is 41.14, which is an increase of 371.79% from the latest price.

Price Target
$41.14
(371.79% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Impel Pharmaceuticals to Participate in 2022 Wedbush PacGrow Healthcare Conference

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases wit...

Impel Pharmaceuticals Announces First Patient Dosed in Phase 2a Study Evaluating INP105 to Treat Acute Agitation in A...

CALM 201 Study to Explore the Safety and Efficacy of Single 5mg-Dose INP105 Compared to Placebo in Quickly Reducing Agitation in Participants with ASD

Impel Pharmaceuticals to Present Trudhesa® Data at the 64th Annual Meeting of the American Headache Society

Oral Presentation Showcases Early Ability to Predict Responders to Trudhesa

Impel Pharmaceuticals To Present At The JMP Securities Life Sciences Conference

SEATTLE, June 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases wit...

Impel Pharmaceuticals Inc. (IMPL) Reports Q1 Loss, Tops Revenue Estimates

Impel Pharmaceuticals Inc. (IMPL) delivered earnings and revenue surprises of -8.33% and 9.94%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

Trudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021

Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...

Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with...

Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation

Impel Celebrates Its One-Year Anniversary as a Public Company Today at the Nasdaq Stock Market Closing Bell Ceremony Starting at 3:45 p.m. EDT Impel Celebrates Its One-Year Anniversary as a Public Compa...

Impel NeuroPharma To Present At The 21st Annual Needham Healthcare Conference

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high u...

Impel NeuroPharma Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Trudhesa™ Exceeds Fourth Quarter 2021 Prescription Guidance; Strong Launch Continues Into 2022 Demonstrated by 157% Growth Since December 31, 2021

Impel NeuroPharma to Present Trudhesa™ Data at 2022 Scientific Meeting of American Academy of Neurology

New Data Suggests Rapid, Sustained, and Consistent Migraine Relief with Trudhesa Treatment

Impel NeuroPharma to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 24, 2022

SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high u...

Impel Neuropharma Announces $100 Million Royalty and Debt Financing Agreement With Oaktree

-Transaction Provides Immediate, Non-Dilutive Capital to Further Support Commercialization of Trudhesa™

Impel NeuroPharma to Participate in Upcoming Virtual Investor Conferences

SEATTLE, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ: IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high un...

Impel NeuroPharma Provides Updates on Trudhesa™ Launch and Recent Business Highlights

Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray for Acute Migraine Delivered Strong Q4 2021 Launch with 4,200 (TRx) Prescriptions; Exceeding Company's Guidance Range

Impel NeuroPharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

Launched Trudhesa™ (dihydroergotamine mesylate) Nasal Spray (0.725 mg per spray) for the Acute Treatment of Migraine with and without Aura in Adults

Phil Announces Partnership with Impel NeuroPharma in Support of Trudhesa™ (dihydroergotamine mesylate) Nasal Spray fo...

SAN FRANCISCO, Sept. 29, 2021 /PRNewswire/ -- Phil, Inc. announces partnership with Impel NeuroPharma, Inc. (NASDAQ: IMPL) in support of Trudhesa™ (dihydroergotamine mesylate) nasal spray (0.725 mg per ...

Carepoint Pharmacy Selected by Impel NeuroPharma as a Digital Pharmacy Partner for the Launch of Trudhesa™ (Dihydroer...

SCHAUMBURG, Ill., Sept. 28, 2021 /PRNewswire/ -- Carepoint Pharmacy announces that it will partner  with Impel NeuroPharma, Inc. (NASDAQ: IMPL)  to begin dispensing Trudhesa™ (dihydroergotamine mesylate...

Impel NeuroPharma Announces Trudhesa™ (Dihydroergotamine Mesylate) Nasal Spray is Now Available for Prescription for ...

Trudhesa is the First and Only Therapeutic to Use POD® Technology to Deliver Dihydroergotamine Mesylate (DHE)—a Proven, Well-Established Therapeutic—to the Vascular-Rich Upper Nasal Space

Why Impel NeuroPharma Dived by 24% Today

For investors, the company's price for a new share issue isn't right.

Impel NeuroPharma To Raise $45M Via Equity Offering

Impel NeuroPharma Inc's (NASDAQ: IMPL) has priced its previously announced underwritten public offering of 3 million shares at $15.00 per share for gross proceeds of $45 million. The offer price represe...

Impel NeuroPharma Announces Pricing of $45.0 Million Public Offering

SEATTLE, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Impel NeuroPharma, Inc. (NASDAQ: IMPL), a commercial-stage biopharmaceutical company developing transformative therapies for people suffering from diseases wi...

Why Impel NeuroPharma Stock Blasted 27% Higher Thursday

A big sell-off in the stock is followed by a sudden bull rush, days after the company wins its first FDA approval.

Why Impel NeuroPharma Gained 17% Today Then Faded

The FDA approval celebration is over, and the real work of selling is about to begin.